Tracey L. Evans, MD of the University of Pennsylvania discusses T790 mutation testing on initial diagnosis. Testing T790M before the first-line is essential and the more you look, the more you will find cells with T790M mutations in EGFR mutated lung cancer patients. This maybe important if youre going with the first or second generation EGFR TKI that doesnt have activity in the T790M setting. However, if osimertinib will be used in the first-line setting, as justified by the FLAURA data, then the testing will not be that essential since osimertinib targets those patients.
T790 Mutation Testing on Initial Diagnosis
